Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
ACMG Letter Regarding South Carolina House Bill 3751 (2017) – Requesting Amendments
-
ACMG Letter Regarding South Carolina Senate Bill 264 (2017) – Requesting Amendments
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG Response to Expansion of Direct-to-Consumer Genetic Testing
-
ACMG Response to FDA’s Proposed Regulatory Framework for LDTs